Vitamin D3 and K2 supplements: a private-label overview

Softgels and oil-based capsules, described above as typical fat-soluble vitamin formats, sit outside DAT Supply's sellable catalogue. The combined D3+K2 formulation is manufactured as a gummy in the current catalogue, and standalone D3 is also available as a functional jelly and an oral strip. A brief calling for a softgel or capsule format has to be re-pointed at one of these formats before it can move to sampling.

This is a meaningful correction to make early in a brief, since softgels and capsules are still the format most associated with D3+K2 in the wider market. A brand owner coming from that expectation should plan around the formats above rather than assuming a softgel line is available here.

A combined D3+K2 gummy SKU keeps a range to a single product and a single serving occasion, which suits a brand wanting the simplest possible bone-health or wellness SKU. Standalone D3 is available in functional jelly or oral strip format for a brand that wants to differentiate D3 from the rest of a range; standalone K2 is currently only available combined with D3 in the gummy, not as its own SKU.

The choice also affects personalisation scope: a combined SKU's Personalization adjustments apply to both actives at once within the gummy's base recipe, while a standalone D3 SKU in a different format can be personalised independently of the combined gummy.

D3+K2 sits within the Daily Vitamins category alongside other single- and multi-active SKUs already in the catalogue, including standalone vitamin C, a zinc-and-magnesium combination and standalone magnesium SKUs. A D3+K2 SKU built in one of the formats above can anchor a broader daily-vitamins range, with adjacent actives added in matching or complementary formats as the range grows.

Reviewing how those adjacent actives are positioned — see the sibling overviews linked below — is a useful reference point before finalising a D3+K2 brief, since it shows how other actives in the same category have been mapped onto the same sellable-format constraints.

The briefing steps described above — target dosage per serving, preferred format, K2 form and ratio — still apply, but naming a sellable format up front (the combined gummy, or a standalone-D3 functional jelly or oral strip) rather than a generic 'capsule or softgel' preference speeds up the formulation review that follows, since the manufacturer can route the brief directly to the right format's base recipe instead of first redirecting a capsule-framed brief to a sellable alternative.

It also helps to flag early whether the brand is aiming for the combined D3+K2 gummy or a standalone D3 SKU in a different format, since that decision affects both the personalisation scope and the number of specification sheets the project will generate later. Naming the format and that choice in the same brief message, rather than across separate follow-up emails, is usually enough for the manufacturer to return a first formulation direction without a clarifying round trip. It also gives the manufacturer's R&D team a clearer starting point when a D3+K2 concept sits alongside other actives in the same range, since format decisions made here tend to shape the format choices made for the rest of the range too.